G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 118 filers reported holding G1 THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $50,935 | -80.5% | 22,340 | -35.1% | 0.00% | – |
| Q1 2022 | $261,000 | -25.4% | 34,400 | +0.3% | 0.00% | – |
| Q4 2021 | $350,000 | -23.9% | 34,300 | 0.0% | 0.00% | – |
| Q3 2021 | $460,000 | -38.9% | 34,300 | 0.0% | 0.00% | – |
| Q2 2021 | $753,000 | -19.7% | 34,300 | -12.1% | 0.00% | – |
| Q1 2021 | $938,000 | +119.2% | 39,000 | +63.9% | 0.00% | – |
| Q4 2020 | $428,000 | -15.9% | 23,800 | -46.0% | 0.00% | – |
| Q3 2020 | $509,000 | -53.3% | 44,100 | -1.8% | 0.00% | -100.0% |
| Q2 2020 | $1,089,000 | +120.0% | 44,900 | 0.0% | 0.00% | – |
| Q1 2020 | $495,000 | -58.3% | 44,900 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $1,187,000 | +9.7% | 44,900 | -5.5% | 0.00% | 0.0% |
| Q3 2019 | $1,082,000 | -25.7% | 47,500 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,456,000 | +229.4% | 47,500 | +78.6% | 0.00% | – |
| Q1 2019 | $442,000 | -20.9% | 26,600 | -8.9% | 0.00% | – |
| Q4 2018 | $559,000 | -64.2% | 29,200 | -2.3% | 0.00% | -100.0% |
| Q3 2018 | $1,563,000 | +20.3% | 29,900 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,299,000 | – | 29,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 719,985 | $31,291,000 | 2.32% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 72,000 | $3,121,000 | 1.20% |
| EMERALD ADVISERS, LLC | 506,424 | $22,009,000 | 0.83% |
| Virtus ETF Advisers LLC | 18,103 | $787,000 | 0.70% |
| Birchview Capital, LP | 22,000 | $956,000 | 0.65% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 352,053 | $15,300,000 | 0.55% |
| Hillhouse Capital Management | 699,431 | $30,397,000 | 0.52% |
| Rock Springs Capital Management LP | 300,000 | $13,038,000 | 0.50% |
| BB BIOTECH AG | 352,607 | $15,324,000 | 0.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 287,000 | $12,473,000 | 0.44% |